Calidi Biotherapeutics CEO Eric Poma, Ph.D., shared insights into the future of systemically delivered oncolytic virotherapy in a recent Xtalks feature.

Calidi Biotherapeutics is developing a new modality in cancer treatment through its proprietary RedTail platform, designed for systemic delivery of modified oncolytic viruses with genetic payloads activated at the tumor site. Focused on patients with limited treatment options, the company is advancing therapies aimed at improving targeting, activity, and durability in solid tumors. Calidi continues to generate data and present at leading scientific meetings as it progresses toward early clinical data.